China Dasheng Biotechnology Company
CDBT · Other OTC · USD
0,10USD
0,00 (0,00 %)Stand 13. Juni, 0:00
Kennzahlen
- Eröffnung
- 0,06
- Vortag
- 0,10
- Tagesspanne
- 0,06 – 0,10
- 52 Wochen
- 0,0003 – 0,15
- Volumen
- 10.000
- Ø Volumen
- 6026
- Börsenwert
- 4,1 Mio. $
- KGV
- -4,2
- Gewinn je Aktie (TTM)
- -0,01
- Dividendenrendite
- 0,0 %
- Beta
- 2,3
- Nächste Zahlen
- –
Finanzen
| USD | FY 2022 | FY 2007 | FY 2006 | FY 2005 | FY 2004 |
|---|---|---|---|---|---|
| Umsatz | 0 | 16,29 Mio. | 0 | 484.838 | 630.692 |
| Herstellungskosten | 0 | 8,79 Mio. | 1620 | 365.030 | 406.695 |
| Bruttogewinn | 0 | 7,5 Mio. | −1620 | 119.808 | 223.997 |
| Forschung und Entwicklung | 0 | 0 | 0 | 0 | 0 |
| Vertrieb und Verwaltung | 560.935 | 2,43 Mio. | 8380 | 136.672 | 246.742 |
| Operatives Ergebnis | −657.000 | 5,08 Mio. | −10.000 | −16.864 | −22.745 |
| EBITDA | −637.000 | 5,7 Mio. | −8380 | −15.244 | −21.125 |
| Nettogewinn | −967.000 | 4,64 Mio. | −68.447 | −16.864 | −22.745 |
| Gewinn je Aktie (verwässert) | -0,02 | 0,15 | -0,01 | -0,00 | -0,00 |
Bewertung
Letzte 12 Monate
- KGV
- -4,2
- Kurs-Umsatz-Verhältnis
- 0,0
- Kurs-Buchwert-Verhältnis
- -3,4
- PEG
- 0,1
- Bruttomarge
- 0,0 %
- Operative Marge
- 0,0 %
- Nettomarge
- 0,0 %
- Verschuldungsgrad
- -0,8
- EV/EBITDA
- -8,0
- Eigenkapitalrendite
- 155,5 %
- Kapitalrendite (ROIC)
- 354,7 %
- Free-Cashflow-Rendite
- −5,7 %
| FY 2022 | FY 2021 | FY 2007 | FY 2006 | FY 2005 | |
|---|---|---|---|---|---|
| Bruttomarge | 0,0 % | 0,0 % | 46,1 % | 0,0 % | 24,7 % |
| Operative Marge | 0,0 % | 0,0 % | 31,1 % | 0,0 % | −3,5 % |
| Nettomarge | 0,0 % | 0,0 % | 28,5 % | 0,0 % | −3,5 % |
| KGV | -3,1 | 0,0 | 13,0 | -200,0 | -1.052,6 |
| Kurs-Umsatz-Verhältnis | 0,0 | 0,0 | 3,6 | 0,0 | 37,5 |
| Kurs-Buchwert-Verhältnis | -2,5 | 0,0 | 3,7 | 0,0 | -47.769,0 |
| Verschuldungsgrad | -0,8 | 0,0 | 0,0 | 0,0 | 0,0 |
| Liquidität 3. Grades | 0,1 | 0,0 | 5,5 | 0,0 | 0,7 |
| Dividendenrendite | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| Unternehmenswert | 4,05 Mio. | 0 | 56,94 Mio. | 0 | 18,19 Mio. |
| EV/EBITDA | -6,4 | 0,0 | 10,0 | 0,0 | -1.193,4 |
| Eigenkapitalrendite | 79,7 % | 0,0 % | 29,6 % | 0,0 % | 4.426,2 % |
| Kapitalrendite (ROIC) | 354,7 % | 0,0 % | 27,1 % | 0,0 % | 0,0 % |
| Free-Cashflow-Rendite | −7,7 % | 0,0 % | 7,0 % | 0,0 % | 0,0 % |
Wachstum
| FY 2022 | FY 2021 | FY 2007 | FY 2006 | FY 2005 | |
|---|---|---|---|---|---|
| Umsatz | 0,0 % | 0,0 % | 0,0 % | −100,0 % | −23,1 % |
| Bruttogewinn | 0,0 % | 0,0 % | +463.309,9 % | −101,4 % | −46,5 % |
| Operatives Ergebnis | 0,0 % | 0,0 % | +50.850,0 % | +40,7 % | +25,9 % |
| Nettogewinn | 0,0 % | 0,0 % | +6.876,0 % | −305,9 % | +25,9 % |
| Gewinn je Aktie | 0,0 % | 0,0 % | +1.600,0 % | −426,3 % | +24,0 % |
| Freier Cashflow | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| Dividende je Aktie | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
Analysten
Einstufungen
Gerade nicht verfügbar.
Kursziel
Gerade nicht verfügbar.
Quartalszahlen
| März 2009 | Dez. 2008 | Sept. 2008 | März 2008 | Dez. 2007 | Juli 2007 | Apr. 2007 | Jan. 2007 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | – | – | – | – | – | – | – | – |
| Gewinn je Aktie · Tatsächlich | 0,04 | 0,06 | 0,04 | 0,01 | 0,05 | -0,00 | -0,00 | -0,00 |
| Abweichung | – | – | – | – | – | – | – | – |
| Umsatz · Tatsächlich | 5,31 Mio. | 5,66 Mio. | 5,11 Mio. | 3,71 Mio. | 4,71 Mio. | 96.560 | 90.270 | 78.955 |
Dividenden und Splits
Keine Dividenden gezahlt.
Aktiensplits
–
Eigentümer
Institutionen
Gerade nicht verfügbar.
Insider-Geschäfte
–
Vergleichbare Unternehmen
Über das Unternehmen
China Dasheng Biotechnology Company, alongside its various divisions, is dedicated to the creation, promotion, and distribution of microbial products within the People's Republic of China. These specialized solutions primarily function as beneficial additives for both livestock feed and agricultural cultivation. The company's product line features proprietary blends of Artificial Microorganisms (AM) and High-efficiency Microorganisms (HM), in addition to biological preservatives. Its AM/HM bacteria-based additives for crops, including specific strains like Bulgaria lactobacillus, beer microzyme, and dark red spirilla, are formulated to significantly boost beneficial microbial populations in soil. They also work to counteract the proliferation of harmful fungi and putrefactive bacteria, thereby optimizing nutrient absorption and helping to reduce the incidence of diseases in both plants and animals. For animal nutrition, the AM/HM bacteria-based feed additives are designed to improve the texture of livestock feed and inhibit the growth of pathogenic bacteria. Moreover, they deliver essential nutrients such as organic acids, vitamins, enzymes, natural antibiotics, mycelial protein, and various other growth-promoting substances to ensure a balanced nutritional profile in the feed. The FGW bacterial preservatives serve a dual purpose: preserving animal specimens for scientific research and extending the shelf life of agricultural produce. Furthermore, the company supplies bacteria-based fertilizers intended for application directly onto plant foliage, particularly for vegetables and fruits. Beyond its biotechnology endeavors, China Dasheng Biotechnology Company also holds investments in the residential and commercial real estate sectors. The enterprise was previously known as Max Nutrition, Inc., before officially adopting its current name, China Dasheng Biotechnology Company, in March 2008. Its operational headquarters are situated in Lanzhou, China.
Führung
- Jinjun QiPresident & Secretary
- Gang ChenChairman of the Board & Chief Executive Officer
- Hongsheng WangChief Financial Officer
- Jingbo GaoVice President of Investor Relations
- CEO
- Gang Chen
- Mitarbeitende
- 689
- Hauptsitz
- Lanzhou, CN
- Sektor
- Financial Services
- Branche
- Shell Companies
- Börsengang
- 13. Feb. 2008
- Website
- chinadashengbio.com
Nachrichten
Gerade keine Nachrichten zu diesem Unternehmen.
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.